The role of autophagic cell death and apoptosis in irinotecan-treated p53 null colon cancer cells
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22721392
DOI
10.2174/1871520611313050015
PII: CMCACA-EPUB-20120618-10
Knihovny.cz E-resources
- MeSH
- Apoptosis drug effects physiology MeSH
- Autophagy drug effects physiology MeSH
- HT29 Cells MeSH
- Antineoplastic Agents, Phytogenic pharmacology therapeutic use MeSH
- HCT116 Cells MeSH
- Irinotecan MeSH
- Camptothecin analogs & derivatives pharmacology therapeutic use MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Tumor Suppressor Protein p53 deficiency genetics MeSH
- Colonic Neoplasms drug therapy genetics metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antineoplastic Agents, Phytogenic MeSH
- Irinotecan MeSH
- Camptothecin MeSH
- Tumor Suppressor Protein p53 MeSH
The roles of autophagic cell death and apoptosis induced by topoisomerase inhibitor irinotecan in colon cancer cells with deleted p53 were investigated during 48 h. We report that irinotecan-dependent cytotoxicity and proapoptotic activity were reduced in the present model while autophagy levels significantly increased. Upon p53 transfection, cell demise rates increased, with cells bearing the features of apoptosis and autophagic cell death. The subsequent studies into mechanisms of cell death process revealed the important role of Bax in mediating mitochondrial and lysosomal leakage which might serve as leading signals for both apoptosis and autophagic cell death. These results suggest that different modes of cell death in p53 null colon cancer cells treated with cytostatics (irinotecan) may be activated simultaneously. Moreover, their interactions possibly occur at several stages and aren't mutually exclusive. This might thus lead to a potential synergism with interesting therapeutic ramifications.
References provided by Crossref.org